CELL INTELLIGENCE · 肿瘤细胞治疗研究

没有 BCMA？没问题：靶向 CD70 的 CAR-NK 细胞在高危骨髓瘤中展现前景

No BCMA? No Problem: A CD70-Targeting CAR-NK Cell Shows Promise in High-risk Myeloma.

靶向 CD70 的 CAR-NK 细胞克服 BCMA 下调并改善高危多发性骨髓瘤模型中的生存

CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma Models.

同种异体嵌合抗原受体（CAR）作为多发性骨髓瘤的“现货型”疗法

Allogeneic chimeric antigen receptors (CARs) as an "off-the-shelf" therapy in multiple myeloma.

多发性骨髓瘤细胞治疗的新方法：聚焦 CAR-T 细胞

Novel Approaches of Cellular Therapy in Multiple Myeloma: Focus on Chimeric Antigen Receptor T-Cells.

CAR-T 细胞疗法在多发性骨髓瘤治疗中显示出显著获益。

加速 CAR-T/NK 治疗可及性——AlloCAR 与快速生产平台是否为改善多发性骨髓瘤可及性的前路？

Accelerating accessibility of CAR-T/NK therapies - Are AlloCARs and rapid manufacturing platforms the road ahead in improving access in multiple myelo

CD38-CAR 人 NK 细胞联合 ATRA 增强对表达 CD38 的血液系统恶性肿瘤的细胞毒性

CD38-CAR human NK cells in combination with ATRA enhance cytotoxicity against CD38-expressing hematologic malignancies.

急性髓系白血病中的过继性细胞治疗：当前范围与挑战

Adoptive Cellular Therapy in Acute Myeloid Leukemia: Current Scope and Challenges.